Pharmaids Pharmaceuticals Officially Appoints Dr. Yogananda Moolemath as Independent Director

Pharmaids Pharmaceuticals Limited has officially confirmed the appointment of Dr. Yogananda Moolemath as Independent Director effective January 01, 2026, following successful shareholder approval through postal ballot. The company has now filed the requisite regulatory disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Postal Ballot Results Overview

The company successfully concluded its postal ballot process on December 31, 2025, with shareholders approving key board appointments and remuneration proposals through remote e-voting. The postal ballot results were declared on January 02, 2026.

Parameter:	Details
Cut-off Date:	November 28, 2025
Total Shareholders:	8,332
Voting Period:	December 2-31, 2025
Scrutinizer:	Mr. Kashinath Sahu
Total Outstanding Shares:	3,52,67,812

Independent Director Appointment Approved

Dr. Yogananda Moolemath's appointment as Independent Director was approved as a Special Resolution with overwhelming support from shareholders. The appointment follows the Board's earlier decision based on the recommendation of the Nomination and Remuneration Committee.

Voting Category:	Votes Polled	Votes in Favour	Approval Rate (%)
Promoter Group:	1,16,26,149	1,16,26,149	100.00
Public Non-Institutions:	1,52,52,011	1,52,51,975	99.9998
Total Votes:	2,68,78,160	2,68,78,124	99.9999

Director Profile and Qualifications

Dr. Yogananda Moolemath brings extensive expertise to the board as a European Registered Toxicologist (ERT) with a PhD in Toxicology and over 30 years of experience in Drug Discovery & Development, toxicology, regulatory science and research leadership.

Professional Details:	Information
DIN:	02870387
Current Role:	Chief Scientific Officer & Co-Founder, Vittartha Life Sciences
Academic Position:	Adjunct Associate Professor, St. John's National Academy of Health Sciences
Term Duration:	5 years as Independent Director
Board Independence:	Not related to any existing Directors

Regulatory Compliance and Disclosure

The company has fulfilled all regulatory requirements under SEBI regulations, with Company Secretary Prasanna Subramanya Bhat confirming the appointment through official communication to BSE Limited. The disclosure confirms that Dr. Moolemath is not debarred from holding directorship by any regulatory authority.

Board Restructuring Progress

With Dr. Moolemath's appointment confirmed, the company's board restructuring initiatives continue to strengthen governance. The appointment complements other recent leadership changes, including the designation of Mr. P.N Vijay as Chairman and Dr. S.N Vinaya Babu as Vice Chairman in December 2025.

The successful completion of the postal ballot process and official appointment marks a significant milestone in Pharmaids Pharmaceuticals' governance enhancement, bringing specialized pharmaceutical industry expertise to the board through Dr. Moolemath's extensive background in drug development and regulatory affairs.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.61%	-0.44%	-9.32%	-16.71%	-41.85%	+223.13%

Pharmaids Pharmaceuticals Limited has undergone a significant change in its shareholding structure following the completion of an open offer. The company has reclassified 12 individuals from the Promoter/Promoter Group category to the Public category, marking a shift in the company's ownership structure.

Open Offer Details

The open offer, conducted by Dr. Shankarappa Nagaraja Vinaya Babu ("Acquirer") and Tumkur Trade Center Private Limited ("PAC"), was completed on September 23, 2025. Following this acquisition, both entities have been classified as the new promoters of Pharmaids Pharmaceuticals Limited.

Reclassification of Promoters

The reclassification involves 12 individuals who collectively held a 5.10% stake in the company. The most notable among these is Sadhanala Venkata Rao, who held the largest individual stake at 4.32%. The complete list of reclassified individuals and their respective shareholdings is as follows:

Name	Previous Category	Shareholding (%)
Sadhanala Venkata Rao	Promoter	4.32
Padmaja Kalyani Sadhanala	Promoter	0.54
Pilli Meena Kumari	Promoter	0.16
Viswa Prasad Sadhanala	Promoter	0.05
Surekha Dave	Promoter Group	0.03
Rangoori Kantham	Promoter	0.00
Sadhanalla Dara Kalyani	Promoter	0.00
Dadi Urmila	Promoter	0.00
Maharani Maheshwari Sadhanala	Promoter	0.00
Baghi Rao Pankaj Sadhanala	Promoter	0.00
Uttam P Jain	Promoter Group	0.00
Suresh Kumar	Promoter Group	0.00

Compliance with Regulations

In accordance with SEBI regulations, the reclassified promoters have confirmed that:

They do not hold more than 10% of the total voting rights in the company.
They do not exercise control over the company's affairs.
They have no special rights through formal or informal arrangements.
They will not be represented on the Board of Directors or act as Key Managerial Personnel for three years from the date of reclassification.

Company Assurances

Pharmaids Pharmaceuticals has assured compliance with several key regulatory requirements:

The company meets the Minimum Public Shareholding requirements as per SEBI regulations.
Its equity shares are not suspended from trading on the stock exchanges.
There are no outstanding dues payable to SEBI, stock exchanges, or depositories.

The reclassification took immediate effect upon the completion of the open offer, as stated in the company's filing with the BSE Limited.

This move represents a significant shift in Pharmaids Pharmaceuticals' ownership structure and could potentially impact the company's future strategic decisions. Investors and market watchers will likely keep a close eye on any further developments or changes in the company's direction following this reclassification.